Comparative Pharmacology
Head-to-head clinical analysis: ANDROID 5 versus ANDROID F.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANDROID 5 versus ANDROID F.
ANDROID 5 vs ANDROID-F
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Androgen receptor agonist; stimulates protein synthesis and growth of androgen-sensitive tissues.
Fingolimod is a sphingosine 1-phosphate receptor modulator that sequesters lymphocytes in lymph nodes, reducing central nervous system immune cell infiltration.
2.5-10 mg orally once daily in the morning for androgen replacement therapy in adult males.
Adults: 1 tablet (methyltestosterone 2.5 mg, ethinyl estradiol 0.025 mg) orally once daily, with food.
None Documented
None Documented
Terminal elimination half-life is 3.5–5.5 hours; clinical effects may persist for several days due to active metabolites.
2.5-3.5 hours (terminal half-life); oral administration may require multiple daily doses for stable levels.
Primarily renal: ~90% as glucuronide and sulfate conjugates, 6% as unchanged drug; ~5% fecal via bile.
Primarily renal (90% as glucuronide and sulfate conjugates, 10% unchanged); small amount biliary/fecal.
Category C
Category C
Androgen
Androgen/Estrogen Combination